Setmelanotide
Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
2 – 3 mg
2 mg
First 2 weeks
3 mg
Ongoing maintenance
Compound profile
Scientific & efficacy data
Weight Management
Peptide profile
Strong human trials
Setmelanotide
2 mg · Once daily
Molecular formula
C49H68N18O9S2
- Mol. weight
- 1,117.3 Da
- CAS number
- 920014-72-8
- PubChem
- 11993702
- Developed · 2020
- Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Amino acid sequence
H-Nle4-D-Phe7-Arg8-Trp9-Lys10(Ac-γ-MSH-analogue)-NH2Weight Management
Dramatic weight reduction (10-23%) in patients with rare genetic obesity by restoring MC4R-mediated satiety signaling that is absent due to upstream pathway mutations
Metabolic Health
Comprehensive metabolic improvement including BMI reduction, improved lipid profiles, and resolution of hyperphagia-driven metabolic dysfunction
Quality of Life
Transformative reduction in insatiable hunger (hyperphagia) that characterizes monogenic obesity, dramatically improving daily functioning and psychosocial wellbeing
Dosing
How much do I take?
2 mg, titrated to 3 mg · once daily
2 – 3 mg
Once daily
Covers all 2 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for treating obesity caused by confirmed pomc deficiency mutations & managing obesity from pcsk1 or lepr genetic defects
Best for
Treating obesity caused by confirmed POMC deficiency mutations
Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing obesity from PCSK1 or LEPR genetic defects
Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hyperphagia and body weight in Bardet-Biedl syndrome
Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Addressing early-onset severe obesity with identified melanocortin pathway mutations
Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Setmelanotide with similar peptides to find the best fit for your goals.
Administration
How do I use it?
subcutaneous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations.
The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity.
Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients.
Safety evidence comes from Phase 3 trials (IMCIVREE, VENTURE) in pediatric and adult populations with confirmed genetic melanocortin pathway defects, with long-term follow-up data supporting chronic administration.
FDA approval in 2020 and EMA approval in 2021 validate the benefit-risk profile in eligible populations. Ongoing Phase 2 studies in hypothalamic obesity, Prader-Willi syndrome, and Alström syndrome continue to characterize safety in expanded indications.
Common side effects · experienced by some users
Skin Hyperpigmentation
The most characteristic side effect, occurring in >60% of patients. Results from off-target activation of MC1R on melanocytes. Manifests as generalized darkening of skin that develops gradually over weeks to months.
Management: Expected pharmacological effect of melanocortin receptor activation. Monitor skin changes at regular intervals. Perform baseline and periodic skin examinations including dermoscopy for nevus surveillance. Hyperpigmentation may partially reverse upon treatment discontinuation.
Injection Site Reactions
Local reactions including erythema, pruritus, induration, and mild pain at the injection site. Reported in approximately 20-30% of patients in clinical trials.
Management: Rotate injection sites between abdomen, thigh, and upper arm. Clean site before injection. Apply cold compress if needed. Reactions typically mild and self-limiting.
Nausea
Reported in clinical trials, typically mild to moderate. May be related to central MC4R-mediated effects on appetite and gastrointestinal motility.
Management: Usually resolves with continued treatment. Take with food if helpful. Slow dose titration may reduce incidence.
Diarrhea
Gastrointestinal disturbance reported in some patients, generally mild and transient.
Management: Maintain adequate hydration. Typically self-limiting and does not require dose adjustment.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Setmelanotide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Setmelanotide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Genetic Counseling — Essential for confirming melanocortin pathway mutations and identifying eligible patients for targeted MC4R agonist therapy
- Safe:Behavioral Therapy — Complementary approach to support dietary and lifestyle modifications alongside pharmacological hunger reduction
- Safe:Nutritional Counseling — Supports healthy eating patterns as hyperphagia resolves and appetite normalizes with treatment
With medications
- Caution:Other MC4R Agonists — Redundant mechanism of action with increased risk of melanocortin-related side effects including excessive hyperpigmentation
- Caution:Medications Affecting Melanocortin Signaling — Potential unpredictable interactions with melanocortin pathway signaling and altered efficacy or safety profile
- Caution:Photosensitizing Agents — May exacerbate skin pigmentation changes and increase risk of melanocytic nevus development in the setting of MC1R activation
With supplements
- Safe:Multivitamins — Generally safe to take alongside Setmelanotide. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-4
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for this use
Onset of effects
Moderate
(1-2 weeks)
How it works
Setmelanotide is a brain hormone activator that works like a master switch for appetite control.
In people with rare genetic defects, this appetite switch gets stuck in the 'on' position, causing extreme hunger and obesity from childhood.
Setmelanotide turns that switch back off by activating the melanocortin-4 receptor in the brain, telling your body to eat less and feel satisfied with smaller meals.
The deeper mechanism
Setmelanotide (RM-493) is a potent, selective agonist of the melanocortin-4 receptor (MC4R), a G-protein coupled receptor expressed predominantly in the paraventricular and dorsomedial hypothalamus.
MC4R activation is critical for appetite suppression and energy expenditure in the leptin-melanocortin signaling pathway.
Setmelanotide directly activates MC4R downstream of POMC neurons, bypassing upstream defects in leptin signaling (LEPR), POMC synthesis (POMC, PCSK1), or leptin signaling intermediates, thereby restoring physiologic appetite suppression in patients with monogenic obesity.
The drug's EC50 for human MC4R is approximately 0.2 nM, making it highly selective and potent.
By activating MC4R on pro-opiomelanocortin (POMC) neurons and other appetite-regulating circuits, setmelanotide reduces hyperphagia, increases satiety, and promotes weight loss specifically in patients with POMC, PCSK1, or LEPR deficiency—conditions that cause severe, treatment-resistant obesity due to leptin-melanocortin pathway dysfunction.
What to expect
Weeks 1-4
What you might notice
- Beginning of dose titration from 0
- 5-1 mg
- Possible early reduction in hunger intensity
- Mild injection site reactions
- Early signs of skin darkening may begin
What's normal
- Appetite changes may be subtle initially during low-dose titration
- Skin hyperpigmentation develops gradually
- Mild nausea or GI changes are common and usually transient
What's next
- Continue dose titration by 0
- 5 mg every 2 weeks
- Monitor body weight, hunger scores, and skin changes
- Target maintenance dose of 2-3 mg
Weeks 4-12
What you might notice
- Meaningful reduction in hyperphagia as dose approaches maintenance level
- Measurable weight loss beginning
- Skin hyperpigmentation becoming more apparent
What's normal
- Hunger reduction is typically the earliest noticeable clinical effect
- Weight loss follows as caloric intake decreases
- Skin darkening continues to develop and is an expected pharmacological effect
What's next
- Achieve maintenance dose (2-3 mg)
- Assess clinical response with weight measurements and hyperphagia questionnaires
- Begin regular dermatological monitoring
Weeks 12-52
What you might notice
- Sustained weight loss with many patients achieving >10% body weight reduction
- Significant and sustained hyperphagia reduction
- Stable skin pigmentation
What's normal
- Weight loss trajectory may vary between genetic subtypes (POMC/PCSK1 patients tend to respond more robustly than LEPR or BBS)
- Hunger suppression is typically well-maintained
- Skin changes stabilize
What's next
- Continue chronic maintenance therapy
- Reassess every 3-6 months
- If <5% weight loss after adequate trial at maximum dose, consider whether to continue
- Long-term treatment required as weight regain occurs upon discontinuation
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Setmelanotide over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
29 registered studies, 3 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 1,933 people took part in the studies that actually administered Setmelanotide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Massachusetts General Hospital
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Rhythm Pharmaceuticals, Inc.
SETmelanotide to improve hypothalamic function in the ROHHAD-syndrome; a proof of concept study in a small mono-center cohort: the ROH-SET Study
Universitair Medisch Centrum Utrecht
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Setmelanotide is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
Who is eligible for setmelanotide treatment?
Setmelanotide is specifically approved for patients aged 6 years and older with obesity caused by genetically confirmed POMC (proopiomelanocortin) deficiency, PCSK1 (proprotein convertase subtilisin/kexin type 1) deficiency, LEPR (leptin receptor) deficiency, or Bardet-Biedl syndrome. Genetic testing to confirm one of these conditions is required before starting treatment. It is not approved for common (polygenic) obesity.
Why does setmelanotide cause skin darkening?
Setmelanotide activates MC4R to reduce appetite, but it also has some activity at MC1R (melanocortin-1 receptor) on skin melanocytes. MC1R activation stimulates melanin production, leading to skin hyperpigmentation. This is similar to how alpha-MSH (the natural ligand) causes tanning. While setmelanotide has ~20-fold selectivity for MC4R over MC1R, the MC1R effect is sufficient to cause noticeable skin darkening in most patients.
What happens if treatment is stopped?
Setmelanotide addresses the symptom (hyperphagia and obesity) but does not correct the underlying genetic defect. If treatment is discontinued, hyperphagia and weight regain are expected to return as MC4R is no longer being directly stimulated. Long-term, continuous treatment is generally necessary to maintain the benefit.
How is setmelanotide different from GLP-1 receptor agonists like semaglutide?
Setmelanotide works through an entirely different mechanism — it targets the melanocortin-4 receptor (MC4R) in the hypothalamus, which is specific to the leptin-melanocortin appetite pathway. GLP-1 agonists like semaglutide work through the incretin system affecting insulin, glucagon, and gastric emptying. Setmelanotide is uniquely effective in patients with genetic defects in the melanocortin pathway where GLP-1 agonists may be less effective, because the fundamental problem is a disruption in MC4R-mediated satiety signaling.
Can setmelanotide be used in children?
Yes, setmelanotide is approved for patients aged 6 years and older with qualifying genetic obesity conditions. The VENTURE trial specifically studied children aged 2-5 years, showing 83% achieved meaningful BMI reduction with a favorable safety profile. Pediatric dosing starts at 0.5 mg once daily with careful titration.
Is genetic testing required before starting setmelanotide?
Yes, genetic testing confirming POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome is required before treatment. Setmelanotide works by bypassing upstream genetic defects in the melanocortin pathway, so it is only effective when these specific mutations are present. Rhythm Pharmaceuticals offers a free genetic testing program (Uncovering Rare Obesity) to help identify eligible patients.
Further reading
History & related research
History · since 2006
The Drug That Finally Fixed the Broken Hunger Switch
A child born with POMC deficiency doesn't just get hungry — their brain never receives the 'stop eating' signal. They can weigh 300 pounds by age ten despite parents' desperate efforts to limit food.
Read the full history of SetmelanotideReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Setmelanotide, on one page.